127 results on '"Leonard, J.P."'
Search Results
2. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
3. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
4. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
5. Toxicity burden score: a novel approach to summarize multiple toxic effects
6. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors
7. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
8. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
9. Four-zone solidification microstructure formed by laser melting of copper thin films
10. Electron microscopy of geometrically confined copper thin films after rapid lateral solidification
11. Characterization of ZnO nanoparticle suspension in water: Effectiveness of ultrasonic dispersion
12. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma
13. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
14. New monoclonal antibodies for non-Hodgkin's lymphoma
15. The effect of minor elements on the growth and electrical properties of NiO on Ni
16. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
17. Microstructure of pulsed laser deposited FePd thin films on amorphous and crystalline substrates
18. Assessment and modeling of aging in electro-absorption distributed Bragg reflector lasers
19. Suppression of dewetting phenomena during excimer laser melting of thin metal films on SiO 2
20. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)
21. MULTI-CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC-486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA
22. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA
23. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO
24. ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP
25. PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN ADVANCED B-CELL MALIGNANCIES
26. Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness”
27. BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE)
28. OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS
29. Retrospective analysis on R-DHAP/OX and ASCT as salvage treatment for relapsed/refractory high-risk follicular lymphoma
30. HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS-A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL
31. THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
32. FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
33. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO.
34. Sociétés et espaces arborés dans le midi méditerranéen
35. Experimental demonstration of composite packet switching on a WDM photonic slot routing network
36. Prospects for coal-based transportation fuels fading fast
37. Texture of Rapidly Solidified Cu Thin Films Studied by SEM EBSD and TEM
38. The Effect of Copper and Ceria Additions on the High Temperature Oxidation of Nickel
39. 173: Stem-Cell Collection Prior to Autologous Stem Cell Transplantation is Improved by Cyclophosphamide in Lenalidomide-Treated Patients with Multiple Myeloma
40. A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non-Hodgkin’s or Hodgkin’s Lymphoma.
41. Laser Lateral Crystallization of Thin Au and Cu Films on SiO2
42. Grid integration studies of a switched reluctance generator for future hardware-in-the-loop experiments.
43. Experimental demonstration of composite packet switching on a WDM photonic slot routing network
44. Modelling Solid Nucleation and Growth In Supercooled Liquid
45. Effect of protein kinase-C activation on the Mg2+-sensitivity of cloned NMDA receptors
46. Gene therapy - the challenge for the future
47. Standard Operating Procedure for the Registration and Computer-Supported Evaluation of Pharmaco-EEG Data
48. Changes in hypothalamic corticotrophin-releasing factor and anterior pituitary pro-opiomelanocortin mRNA during the course of experimental allergic encephalomyelitis
49. Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis
50. A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non-Hodgkin's or Hodgkin's Lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.